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OBJECTIVES: To assess the prevalence and adequacy of warfarin use in patients with 
atrial ﬁbrillation (AF) according to stroke risk, as assessed by CHADS2 scores, in a 
nationally representative patient sample. METHODS: The data source was GE’s 
Medical Quality Improvement Consortium (MQIC) database (February 2009) con-
taining electronic medical records (EMRs) data on 11 million patients in the U.S. 
Eligible patients were those with a diagnosis of AF, qage 40 years at AF diagnosis, 
and with no use of warfarin or antiplatelet agents at anytime prior to AF diagnosis. 
Ineligible patients were those who might have other reasons, such as cancer or ortho-
pedic surgery, to be hypercoagulable (i.e. other justiﬁcations for different anticoagu-
lant use or INR ranges), or those already on antiplatelet agents or warfarin prior to 
AF diagnosis. CHADS2 stroke risk scores were assigned on the basis of conditions 
prior to or coincident with the AF diagnosis (congestive heart failure, hypertension, 
diabetes mellitus, stroke/TIA). The last INR on record was captured for all eligible 
patients. RESULTS: From 11,196,881 total patients, 58,848 patients with AF met all 
selection criteria. Patients at high risk of stroke (CHADS2 q 2) comprised 99%   
(58,214) of the total patients. Among the high risk patients, 24,953 (43%) were on 
warfarin, 8,541 (15%) antiplatelet agents, and 24,720 (42%) neither. Of the 24,953 
patients on warfarin, the last INR on record was in the suboptimal range (2) in 
13,198 (53%), above optimal range (3) in 2,969 (12%), and in optimal range (2–3) 
in 8786 (35%). CONCLUSIONS: Analysis of a large, nationally representative EMR 
database suggests that the majority of AF patients at increased risk of stroke are 
receiving suboptimal anticoagulation.
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OBJECTIVES: Heart failure is a frequent cause of hospitalisation among older 
patients. This study examines the principal factors leading to acute decompensation 
of heart failure leading to hospital admission and considers whether these factors 
are avoidable. METHODS: We conducted a retrospective casenote study of all 
patients admitted to the department of Geriatric Medicine over a 2 year period 
who had a principal discharge diagnosis of heart failure (ICD codes 428.0, 428.1, 
428.9). Demographic and clinical data on medical history, clinical examination, 
radiographic ﬁndings, echocardiography, blood tests and medications was collected. 
Each case was evaluated to determine the factor that contributed most to heart 
failure decompensation. Main factors leading to hospitalisation included: volume 
overload if patient had all signs of hypervolaemia (pedal oedema, elevated jugular 
venous pressure, pulmonary crepitations and dilutional hyponatraemia), tachyarrhyth-
mia if heart rate was 150 beats per minute, or uncontrolled hypertension if systolic 
blood pressure 180mmHg. RESULTS: The study sample included 145 patients. 
Mean (SD) age was 82(5) years and 74 (51%) were women. All patients were taking 
diuretics and 75 (51.5%) were taking angiotensin converting enzyme inhibitors. 
Twenty two (15.2%) were taking non steroidal anti-inﬂammatory drugs (NSAIDs). 
Risk factors for admission were identiﬁed in this rank order: volume overload 52 
(35.9%) patients, chest infection 26 (17.9%) patients, combination of volume over-
load and chest infection 19 (13.1%) patients, myocardial infarction 17 (11.7%) 
patients, tachyarrhythmia (mainly atrial ﬁbrillation) 9 (6.2%) patients, uncontrolled 
hypertension 10 (6.9%) and pulmonary embolus 1 (0.7%). In 11 (7.6%) patients 
no precipitating factor could be determined. Of the 52 patients with volume overload 
12 (23.1%) were receiving NSAIDs on admission. CONCLUSIONS: Our ﬁndings 
show that factors leading to hospitalisation for heart failure may be amenable 
to intervention, particularly volume overload. Patient education regarding diet 
and medication, especially NSAIDs, and regular monitoring of blood pressure should 
be considered.
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OBJECTIVES: To estimate the threshold of relative stroke risk needed that makes 
medical management inferior to protected carotid stenting in asymptomatic patients 
with carotid artery stenosis and substantial cardiovascular comorbidities. METHODS: 
A validated and published Monte Carlo microsimulation model created a stroke-free, 
two-year survival curve in monthly increments for a hypothetical medically managed 
arm of a recent single-arm carotid revascularization trial in patients at high surgical 
risk due to their cardiovascular comorbidities. Using a log rank test the actual two-year 
survival curve from the ACCULINK for Revascularization of Carotids in High-Risk 
patients (ARCHeR) trial data was compared to the medically-managed curve gener-
ated by the model. The model stroke risk equations were generated from the general 
population and calibrated for patients with asymptomatic carotid artery stenosis but 
otherwise healthy. Relative stroke risks between these patients and the surgical high-
risk patients were estimated from the stroke rates of the intervention arm of a trial 
with more restrictive inclusion criteria (ACAS) and the strokes rates of ARCHeR. 
RESULTS: Using the best estimate of relative risk (2.02) the one- and two-year stroke 
rates for medical management were 0.901 and 0.851, respectively. This compares to 
0.934 and 0.879 from the ARCHeR trial using protected carotid stenting. The Chi-
square statistic from the log rank test of two-year survival curves was 2.26; p  0.13 
that medical management produces different results from carotid stenting. As long as 
the relative risk is greater than 2.25 the p value is 0.05. CONCLUSIONS: Recent 
carotid stenosis trials lack medically managed populations, but a model can estimate 
stroke-free survival and mortality data for these patients if the relative risk compared 
to a known population can be estimated. Since the ARCHeR trial found no ipsilateral 
strokes in its third year, this two-year analysis may overestimate the relative risk 
needed to justify carotid stenting.
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OBJECTIVES: Due to serious cardiopulmonary reactions reported immediately 
following administration of perﬂutren containing contrast agents , the United States 
Food and Drug Administration (FDA) required a Black Box Safety warning for 
this class of agents including Perﬂutren Protein-Type A Microspheres Injectable 
Suspension , USP. The FDA has requested a database analysis to compare in-hospital 
mortality in critically ill patients undergoing echocardiography with and without 
this contrast agent. This study provides results of the retrospective analysis. 
METHODS: This study utilized the largest hospital service-level database in the US. 
All adult patients undergoing inpatient echocardiography between January 2003 
and October 2005 were identiﬁed (n  2 ,588 ,722 of which 22 ,499 received 
Perﬂutren Protein-Type A Microspheres Injectable Suspension, USP). From the 22 ,499 
contrast echocardiography patients, 2,900 had diagnoses meeting criteria for critical 
illness (heart failure, acute myocardial infarction, arrhythmia, respiratory failure, 
pulmonary embolism, emphysema , and pulmonary hypertension). To control for 
the differences between the contrast and non-contrast patients we used propensity 
score matching. Variables used in the construction of the propensity score included 
comorbidities , demographic factors , hospital-speciﬁc factors , level of care, and 
mechanical ventilation status. Patients receiving contrast echocardiography were 
matched to 4 controls who received non-contrast echocardiography. Conditional 
logistic regression was used to estimate mortality effects. RESULTS: There were 167 
deaths in the study among critically ill patients, 38/2900 from the contrast group and 
129/11600 from the control group. The contrast agent was not associated with an 
increase in same-day mortality (odds ratio  1.18 (95% C.I. 0.82, 1.71); P  0.37)). 
Prior to matching, contrast patients showed greater morbidity then non-contrast 
patients (Deyo-Charlson Comorbidity Score 2.45 vs. 2.25, P  0.0001). After propen-
sity-score matching these differences were signiﬁcantly reduced, showing that both 
groups were well-balanced. CONCLUSIONS: There is no increase in mortality in 
critically ill patients undergoing echocardiography with the contrast agent compared 
to case-matched controls.
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OBJECTIVES: Health beneﬁts of low-density lipoprotein cholesterol (LDL-C) at rec-
ommended levels are well known; beneﬁts of HDL-C at recommended levels are less 
well documented. This study assesses and replicates the quantiﬁcation of the relation-
ship between HDL-C and all-cause mortality while aligning relative importance to 
LDL-C. METHODS: A comprehensive analyses of available epidemiological studies 
including HDL-C and all-cause mortality as an endpoint were included in a meta-
regression. That meta-regression was independently validated with a longitudinal 
analysis of an Australian epidemiological database (General Practitioner Research 
Network) 1999–2008. While statistical association is important, demonstration that 
modiﬁcations via intervention to the clinical measure (HDL-C) effect change in the 
endpoint is more important. RESULTS: Twenty-two epidemiological studies in 
153,798 patients met the criteria. In a survival analysis for time to death, higher 
HDL-C is signiﬁcantly associated with longer duration to death (P  0.043); 
0.33 mmol/L higher HDL and 1.33 lower total/HDL cholesterol were each associated 
with about a third lower vascular mortality. Twenty-ﬁve placebo-controlled interven-
tion trials yielded a regression that explained 83% of the variation in percent changes 
in cardiovascular events with parameter estimates associated with percent changes in 
